Castle Biosciences (CSTL) Common Equity (2018 - 2026)

Castle Biosciences (CSTL) has 9 years of Common Equity data on file, last reported at $461.4 million in Q1 2026.

• Quarterly Common Equity rose 4.79% year-over-year to $461.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $461.4 million (up 4.79% YoY) and the FY2025 annual result came in at $470.9 million, up 3.3% from the prior year.
• Common Equity retreated to $461.4 million in Q1 2026 per CSTL's latest filing, from $470.9 million in the prior quarter.
• The five-year high for Common Equity was $470.9 million in Q4 2025, with the low at $378.8 million in Q2 2023.
• Average Common Equity over 5 years is $422.9 million, with a median of $421.7 million recorded in 2022.
• Year-over-year, Common Equity declined 10.17% in 2023 and gained 16.5% in 2024.
• Castle Biosciences' Common Equity stood at $399.2 million in 2022, then fell by 1.97% to $391.3 million in 2023, then rose by 16.5% to $455.8 million in 2024, then increased by 3.3% to $470.9 million in 2025, then fell by 2.01% to $461.4 million in 2026.
• Business Quant data shows CSTL's Common Equity at $461.4 million in Q1 2026, $470.9 million in Q4 2025, and $467.0 million in Q3 2025.